naltrindole

delta opioid receptor antagonist

Also Known As:

17-cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'-indolomorphinan; natrindole hydrochloride; 4,8-Methanobenzofuro(2,3-a)pyrido(4,3-b)carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (8R-(4bS*,8alpha,8abeta,14bbeta))-

Networked: 126 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Xia, Ying: 9 articles (01/2019 - 06/2002)
2.	Chao, Dongman: 3 articles (05/2014 - 02/2007)
3.	Bazzy-Asaad, Alia: 3 articles (07/2007 - 02/2007)
4.	Suzuki, T: 3 articles (01/2006 - 01/2001)
5.	Loh, Horace H: 2 articles (06/2019 - 12/2004)
6.	Li, Yize: 2 articles (02/2018 - 01/2015)
7.	Caffrey, James L: 2 articles (03/2016 - 09/2003)
8.	Suzuki, Tsutomu: 2 articles (07/2015 - 03/2014)
9.	Barrot, Michel: 2 articles (08/2010 - 11/2008)
10.	Yalcin, Ipek: 2 articles (08/2010 - 11/2008)

Related Diseases

1.	Hypoxia (Hypoxemia) 01/01/2019 - "DOR inhibition with naltrindole attenuated the effects of DOR activation on the changes in ERK1/2 and p38 phosphorylation in hypoxia. " 01/01/2019 - "DOR inhibition with naltrindole had no appreciable effect on the hypoxia-induced changes in ERK1/2 phosphorylation, but increased p38 phosphorylation. " 08/25/2009 - "In contrast, CTAP and Naltrindole did not change Tb during hypoxia but caused a longer latency for the return of Tb to the normoxic values just after low O2 exposure. " 11/01/2008 - "We examined the effect of DOR blockade with naltrindole (1-10 micromol l(-1)) on E(m), NMDAR activity and [Ca(2+)](c) homeostasis in turtle cortical neurons during normoxia and the transition to anoxia. " 05/29/2007 - "Along with the injury, either by hypoxia or naltrindole, phosphorylated p38 increased in a major way, while phosphorylated ERK and JNK had no significant change or slightly decreased. "
2.	Infarction (Infarctions) 06/01/2008 - "When naltrindole was combined with EA, the naltrindole completely abolished the EA-induced protection in ischemic infarction and neurological deficits, and also arrested the expression of DOR. " 01/01/2018 - "Conversely, naltrindole abolished Tan-67 neuroprotection in infarct volume. " 02/01/2008 - "In open chest rats, postconditioning reduced infarct size, an effect that was reversed by both naloxone and naltrindole. " 02/01/2000 - "However, higher dose DADLE (1 micromol/L) had a less beneficial effect, and in conjunction with the delta-antagonist naltrindole unexpectedly increased infarct size (61.5 +/- 2.0%, p<0.05 v 45.9 +/- 2.4% in controls) suggesting a non-delta effect. " 01/01/2001 - "In the first series of experiments, it was found that IP with two cycles of 5-min regional ischemia followed by 5-min reperfusion each reduced infarct size induced by 30-min ischemia, and the ameliorating effect of IP on infarct was attenuated with blockade of either 5 x 10(-6) mol/l nor-binaltorphimine (nor-BNI), a selective kappa-OR antagonist, or 5 x 10(-6) mol/l naltrindole (NTD), a selective delta-OR antagonist. "
3.	Ischemia 01/01/2021 - "Importantly, all the beneficial effects of DADLE on ischemia-induced cellular, synaptic, and molecular deficits were eliminated by the DOR inhibitor naltrindole (2.5 nmol). " 06/01/2008 - "Other 12 rats were randomly divided into sham ischemia group, ischemia group, EA group and EA + naltrindole group. " 06/01/2008 - "Fifty-one rats were randomly divided into sham ischemia group, ischemia group, sham EA group, EA group, and EA+DOR antagonist (naltrindole) group. " 10/01/2003 - "Delta-opioid preconditioning of HL-1 myocytes significantly decreased necrosis from in vitro simulated ischemia/reperfusion as measured by LDH release; this effect was reversed by delta-antagonist naltrindole. " 01/01/2001 - "In the first series of experiments, it was found that IP with two cycles of 5-min regional ischemia followed by 5-min reperfusion each reduced infarct size induced by 30-min ischemia, and the ameliorating effect of IP on infarct was attenuated with blockade of either 5 x 10(-6) mol/l nor-binaltorphimine (nor-BNI), a selective kappa-OR antagonist, or 5 x 10(-6) mol/l naltrindole (NTD), a selective delta-OR antagonist. "
4.	Hypoglycemia (Reactive Hypoglycemia) 12/01/2005 - "In contrast, restoration was significantly improved when the opioid receptor antagonists funaltrexamine (mu) or naltrindole (delta) were administered prior to and during hypoxia/hypoglycemia. "
5.	Arterial Occlusive Diseases (Arterial Occlusive Disease) 12/10/2001 - "The improved vagal function was reversed or reduced, respectively, when naltrindole or glibenclamide was included in the microdialysis inflow during arterial occlusion. "

Related Drugs and Biologics

1.	Narcotic Antagonists (Opioid Antagonists)
2.	Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)
3.	Remifentanil (Ultiva)
4.	Glyburide (Glibenclamide)
5.	17- cyclopropylmethyl- 6,7- didehydro- 4,5- epoxy- 5'- guanidinyl- 3,14- dihydroxyindolo(2',3'- 6,7)morphinan
6.	Enkephalins
7.	Naltrexone (ReVia)
8.	isothiocyanic acid
9.	norbinaltorphimine
10.	Naloxone (Narcan)

Related Therapies and Procedures

1.	Analgesia
2.	Ischemic Postconditioning
3.	Therapeutics
4.	Spinal Injections
5.	Intra-Articular Injections